Gemcabene
CAS No. 183293-82-5
Gemcabene( PD-72953 | PD72953 )
Catalog No. M12827 CAS No. 183293-82-5
Gemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 64 | Get Quote |
|
| 5MG | 98 | Get Quote |
|
| 10MG | 165 | Get Quote |
|
| 25MG | 303 | Get Quote |
|
| 50MG | 503 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGemcabene
-
NoteResearch use only, not for human use.
-
Brief DescriptionGemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP.
-
DescriptionGemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP; down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism, inhibits IL-6 plus IL-1β-induced CRP production in a concentration-dependent manner in human hepatoma cells, reaching 70% inhibition at 2 mM; lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), attenuates osteoarthritis and pain in animal models of arthritis and Pain.Hypercholesterolemia Phase 2 Clinical.
-
In VitroGemcabene calcium (PD-72953 calcium) significantly downregulates hepatic mRNA markers of inflammation (TNF-α, MCP-1, MIP-1β, CCR5, CCR2, NF-κB), lipogenesis and lipid modulation (ApoC-III, ACC1, ADH-4, Sulf-2), and fibrosis (TIMP-1 and MMP-2).
-
In Vivo——
-
SynonymsPD-72953 | PD72953
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorPARP
-
Research AreaCardiovascular Disease
-
IndicationHypercholesterolemia
Chemical Information
-
CAS Number183293-82-5
-
Formula Weight302.411
-
Molecular FormulaC16H30O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (330.68 mM)
-
SMILESO=C(O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O
-
Chemical Name6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bisgaier CL, et al. J Lipid Res. 1998 Jan;39(1):17-30.
2. Bays HE, et al. Am J Cardiol. 2003 Sep 1;92(5):538-43.
3. Yuan H, et al. J Pharmacol Exp Ther. 2009 Jul;330(1):191-7.
4. Srivastava RAK, et al. Front Pharmacol. 2018 May 11;9:471.
molnova catalog
related products
-
PARP-1-IN-2
PARP-1-IN-2 is a potent PARP1 inhibitor that crosses the blood-brain barrier (IC50: 149 nM).PARP-1-IN-2 showed significant antiproliferative activity against the human lung adenocarcinoma epithelial cell line A549 in cellular assays.
-
Senaparib
Senaparib is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity.
-
MK-4827 hydrochlorid...
A highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2.
Cart
sales@molnova.com